Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Adhera Therapeutics Inc (ATRX)

Adhera Therapeutics Inc (ATRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin Globe Newswire - Tue Jul 19, 2022

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.345 (+1.47%)
ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ Globe Newswire - Thu May 19, 2022

Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical...

OTC.VN : 0.345 (+1.47%)
ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board Globe Newswire - Mon Mar 21, 2022

Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.345 (+1.47%)
ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace Globe Newswire - Thu Jan 20, 2022

Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.345 (+1.47%)
ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders Globe Newswire - Mon Nov 22, 2021

Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.345 (+1.47%)
ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors Globe Newswire - Mon Nov 8, 2021

Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.345 (+1.47%)
ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications Globe Newswire - Wed Oct 20, 2021

Adhera has an exclusive license agreement with Melior Pharmaceuticals I, pursuant to which Adhera is advancing MLR-1023 (tolimidone) into Phase 2 trials...

OTC.VN : 0.345 (+1.47%)
ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs Globe NewsWire - Mon Sep 13, 2021

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an update...

ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors Globe NewsWire - Thu Sep 9, 2021

Baton Rouge, LA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment...

ATRX : 0.0075 (+11.94%)
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate Globe NewsWire - Tue Aug 24, 2021

Baton Rouge, LA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Company...

ATRX : 0.0075 (+11.94%)

Barchart Exclusives

Guess vs. Levi Strauss: Which Breakout Dividend Stock Is a Better Buy? Barchart - 1 hour ago
With Levi Strauss and Guess stock prices surging and both apparel giants impressing shareholders with their dividend payments, which of the two is a better buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot